Longer-term imatinib treatment extends OS among patients with GIST
Click Here to Manage Email Alerts
An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.
The finding suggests continuing imatinib treatment for 3 years — rather than stopping after 1 year — could reduce by half the number of patients who die during the first decade of follow-up after surgery.
“The current National Comprehensive Cancer Network guidelines recommend postoperative imatinib for at least 3 years after surgical removal of GIST with features that suggest a high risk for recurrence,” Heikki Joensuu, MD, PhD, professor of oncology at University of Helsinki, told Healio. “These recommendations were influenced by the Scandinavian Sarcoma Group XVIII/German (SSGXVIII/AIO) trial that compared 3 years of adjuvant imatinib with 1 year of adjuvant imatinib. In the prior analyses of the SSGXVIII/AIO trial, OS was longer in the 3-year group vs. the 1-year group after median patient follow-up durations of 54 months and 90 months.”
In the current analysis of the SSGXVIII/AIO trial, Joensuu and colleagues assessed whether the survival advantage of the 3-year group persisted after 10 years of follow-up.
The open-label, randomized, multicenter phase 3 trial included 400 patients with macroscopically completely excised GIST and high risk for recurrence. After surgery, researchers assigned patients to 400 mg daily imatinib for 1 year or 3 years.
RFS served as the primary endpoint. Secondary endpoints included OS and safety.
Median follow-up was 119 months. During this time, 18 patients in the 1-year group and 23 patients in the 3-year group were excluded from the study.
Investigators observed 194 RFS events and 96 OS events in the intention-to-treat population.
Researchers reported higher RFS rates in the 3-year imatinib group at 5 years (71% vs. 53%) and 10 years (53% vs. 42%; HR = 0.66; 95% CI, 0.49-0.87).
Results also showed higher OS rates in the 3-year imatinib group at 5 years (92% vs. 79%) and 10 years (86% vs. 65%; HR = 0.55; 95% CI, 0.37-0.83).
Results of a subgroup analysis that excluded 15 patients who did not have GIST per central pathology review and 24 patients with intra-abdominal metastases removed at surgery showed 10-year OS of 81.6% in the 3-year group and 66.8% in the 1-year group (HR = 0.5; 95% CI, 0.32-0.8).
“We found that 3 years of adjuvant imatinib improved OS compared with 1 year of imatinib after a median 10 years of follow-up since the date of randomization,” Joensuu told Healio. “Approximately 50% of deaths from any cause were avoided with the longer treatment, which suggests that 3 years of adjuvant imatinib should be considered for [patients with GIST] who have a high estimated risk for GIST recurrence and whose tumor harbors an imatinib-sensitive KIT or PDGFRA gene mutation.
“Adjuvant imatinib treatment durations of longer than 3 years have not been evaluated in the treatment of GIST in randomized trials,” Joensuu added. “However, there are two ongoing randomized trials comparing 5 or 6 years of adjuvant imatinib with 3 years of imatinib.” – by Jennifer Southall
Collapse
Joensuu H., et al. Abstract 11503. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
Read more about
Click Here to Manage Email Alerts